The increasing complexity of cancer chemotherapy makes it mandatory that pharmacists be familiar with these highly toxic agents. This column focuses on the commercially available and investigational agents used to treat malignant diseases and reviews issues related to the preparation, dispensing, and administration of cancer chemotherapy.
Get full access to this article
View all access options for this article.
References
1.
MoralesA., EidingerD., BruceA.W.Intracavitary bacillus calmette-guerin in the treatment of superficial bladder tumours. J Urol.1976; 116: 180–3.
2.
SmithJ.A., LabaskyR.F., CockettA.T.K.Bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis). J Urol.1999; 162: 1697–702.
3.
National Comprehensive Cancer Network.NCCN bladder cancer practice guidelines v.1.2004. The Complete Library of NCCN Oncology Practice Guidelines [CD-ROM]. Rockledge, PA: National Comprehensive Cancer Network; 2004.
4.
LammD.L., BlumensteinB.A., CrawfordE.D.A randomized trial of intravesical doxorubicin and immunotherapy with Bacille Calmette-Guerin for transitional cell carcinoma of the bladder. N Engl J Med.1991; 325: 1205–9.
5.
LammD.L., BlumensteinB.A., CrawfordE.D.Randomized intergroup comparison of bacillus calmette-guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder. A Southwest Oncology Group study. Urol Oncol.1995; 1: 119–26.
6.
MalmastromP., WijkstromH., LundholmC.Five-year follow-up of a randomized prospective study comparing mitomycin C and bacillus calmette guerin in patients with superficial bladder carcinoma. J Urol.1999; 161: 1124–7.
7.
LundholmC., NorlenB.J., ElkmanP.A randomized prospective study comparing long-term intravesical instillations of mitomycin C and bacillus calmette-guerin in patients with superficial bladder carcinoma. J Urol.1996; 156: 368–76.
8.
Martinez-PineiroJ.A., LeonJ.J., Martinez-PineiroL.Bacillus calmette-guerin versus doxorubicin versus thiotepa: A randomized prospective study in 202 patients with superficial bladder cancer. J Urol.1990; 143: 502–6.
9.
MelekosM.D., ZarakovitisI., DandinisK.BCG versus epirubicin in the prophylaxis of multiple superficial bladder tumors: Results of a prospective randomized study using modified treatment schemes. Int Urol Nephrol.1996; 28: 499–509.
10.
MelekosM.D., ZarakovitisI.E., FokaefsE.D.Intravesical bacillus calmette-guerin versus epirubicin in the prophylaxis of recurrent and/or multiple superficial bladder tumors. Oncology.1996; 53: 281–8.
11.
RintalaE., JauhianinenK., AlfthanO.Intravesical chemotherapy (mitomycin C) versus immunotherapy (bacillus calmette-guerin) in superficial bladder cancer. Eur Urol.1991; 20: 19–25.
12.
VegtP.D., WitjesJ.A., WitjesW.P.J.A randomized study of intravesical mitomycin C, bacillus calmette-guerin Tice and BCG-RIVM treatment of pTa-pT1 paillary carcinoma and carcinoma in situ of the bladder. J Urol.1995; 153: 929–33.
13.
WitjesJ.A., MeijdenA.P.M., ColleteL.Long-term follow-up of an EORTC randomized prospective trial comparing intravesical bacillus calmette-guerin RIVM and mitomycin C in superficial bladder cancer. Urol.1998; 52: 403–10.
14.
GriffithsT.R.L., CharltonM., NealD.E.Treatment of carcinoma in situ with intravesical bacillus calmette-guerin without maintenance. J Urol.2002; 167: 2408–12.
15.
DavisJ.W., ShethS.I., DoviakM.J.Superficial bladder carcinoma treated with bacillus calmette-guerin: Progression-free and disease specific survival with minimum 10-year follow-up. J Urol.2002; 167: 494–501.
16.
LammD.L., BlumensteinB.A., CrissmanJ.D.Maintenance bacillus calmette-guerin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: A randomized Southwest Oncology Group study. J Urol.2000; 163: 1124–9.
